PENTAGASTRIN STIMULATED CALCITONIN TESTING IN MTC AND MEN 2

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本方案旨在对多发性内分泌瘤2A或2B家族成员和接受甲状腺切除术的ret原癌基因阳性患者进行系统随访（使用pentagastrin刺激的降钙素水平）。这包括接受预防性甲状腺切除术的年轻患者（例如，在明显的甲状腺髓样癌发展之前，根据高危基因型进行甲状腺切除术），因为甲状腺髓样癌接受手术治疗。因此，研究的问题涉及到预防性甲状腺切除术在遗传易感人群中预防甲状腺髓样癌的疗效，以及积极性甲状腺切除术治疗家族性甲状腺髓样癌的疗效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol is designed to provide systematic follow-up (with pentagastrin-stimulated calcitonin levels) of ret proto-oncogene positive patients who are members of Multiple Endocrine Neoplasia 2A or 2B families and who have undergone thyroidectomy. These include young patients who have undergone prophylactic thyroidectomy (e.g., thyroidectomy based on the at-risk genotype before the development of demonstrable medullary thyroid carcinoma) as those treated surgically for medullary thyroid carcinoma. Thus, the research questions relate to the efficacy of prophylactic thyroidectomy in the prevention of medullary thyroid carcinoma in genetically at-risk individuals and the efficacy of aggressive thyroidectomy in the treatment of familial medullary thyroid carcinoma.